Methods for treating neovascular age-related macular degeneration

The invention relates to methods for treating neovascular age-related macular degeneration (nAMD) in a patient, the methods comprising (a) administering to the patient as a loading phase of two individual doses of a VEGF antagonist at 6-week interval (q6w regimen), (b) assessing the patient for dise...

Full description

Saved in:
Bibliographic Details
Main Authors KEARNS, JEFFREY DAVID, OLGAC, UFUK, PIGEOLET, ETIENNE, MULYUKOV, ZUFAR
Format Patent
LanguageChinese
English
Published 01.10.2023
Subjects
CHEMISTRY
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
ORGANIC CHEMISTRY
PEPTIDES
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online AccessGet full text

Cover

More Information
Summary:The invention relates to methods for treating neovascular age-related macular degeneration (nAMD) in a patient, the methods comprising (a) administering to the patient as a loading phase of two individual doses of a VEGF antagonist at 6-week interval (q6w regimen), (b) assessing the patient for disease activity after the second dose of the loading phase, and (c) optionally if presence of disease activity is identified after the second dose of the VEGF antagonist, the method further comprises administering to the patient as part of the loading phase a third dose of the VEGF antagonist 6 weeks after the second dose.
Bibliography:Application Number: TW202312109645